Another Monday, another bit of good news from a Covid vaccine trial. It’s Groundhog Day – over and over (Could JNJ news be up next Monday?).
This time it was AstraZeneca plc (AZN) that released preliminary data on the vaccine against Covid-19 that it’s been working on with Oxford University. Unlike Pfizer Inc.’s (PFE) and Moderna Inc.’s (MRNA) two vaccines that scored around 95% and 94.5% efficacy rates, AstraZeneca’s has an efficacy of about 70%. The AZN vaccine does have some distribution benefits since it requires only standard refrigeration.
If anything, this latest bit of news is even more impressive than what we’ve seen before. Pfizer and Moderna used new mRNA technology to get vaccines for Covid-19 out in record time.
Meanwhile, AstraZeneca and Oxford University used existing vaccine technology to make a vaccine in under a year, rather than the several years it usually takes. So did Johnson & Johnson (JNJ), which should be announcing its preliminary results soon as well.